Genentech: Tecentriq Misses Endpoint in Muscle-Invasive Urothelial Cancer
January 24 2020 - 07:52AM
Dow Jones News
By Colin Kellaher
Roche Holdings AG's (ROG.EB) Genentech unit on Friday said a
Phase 3 study of Tecentriq as an adjuvant monotherapy treatment
missed its primary endpoint of disease-free survival in people with
muscle-invasive urothelial cancer.
The company said safety for Tecentriq appeared consistent with
the known safety profile of the immunotherapy drug, with no new
safety signals identified.
"Reducing the risk that muscle-invasive urothelial cancer will
recur after surgery is very difficult, and we are disappointed that
we were not able to significantly prolong disease-free survival,"
Genentech said.
Genentech is conducting an extensive development program for
Tecentriq, including ongoing and planned Phase 3 studies across
bladder, genitourinary, skin, breast, gastrointestinal,
gynecological and head and neck cancers.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 24, 2020 07:37 ET (12:37 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2023 to Mar 2024